Abstract
Urotensin II (U-II) is a cyclic peptide isolated from a fish. Subsequently, human U-II and its receptor were identified. In rat thoracic aorta U-II triggers powerful vasoconstrictor activity. However, the constrictor response to U-II appears to be variable and highly dependent on the vascular bed examined. Vasoconstriction is not its only effect; U-II and its receptor have been demonstrated in the central nervous system, where U-II induces a cardiovascular, behavioural, motor and endocrine response and in the kidney, where it seems to influence renal hemodynamics but also salt and water excretion, in rat pancreas where it inhibits insulin secretion, in the heart where it seems to play a role in cardiac hypertrophy and fibrosis. In humans high plasma or urine levels of U-II have been described in some pathologic conditions. Peptidic and non peptidic UT receptor antagonists have been synthesized and their effects have been evaluated particularly in animal models of diabetes and heart failure. After promising results in animal models, palosuran, a non peptidic U-II antagonist has been administered also in diabetic patients to evaluate its potential nephroprotective activity. This review presents the data available on the U-II system and its role in physiological and pathological conditions, together with data regarding palosuran and other non peptidic and peptidic U-II antagonists.
Keywords: Urotensin II, palosuran, urotensin II related peptide, kidney, heart, blood vessels
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Volume: 6 Issue: 2
Author(s): Alessandro Cosenzi
Affiliation:
Keywords: Urotensin II, palosuran, urotensin II related peptide, kidney, heart, blood vessels
Abstract: Urotensin II (U-II) is a cyclic peptide isolated from a fish. Subsequently, human U-II and its receptor were identified. In rat thoracic aorta U-II triggers powerful vasoconstrictor activity. However, the constrictor response to U-II appears to be variable and highly dependent on the vascular bed examined. Vasoconstriction is not its only effect; U-II and its receptor have been demonstrated in the central nervous system, where U-II induces a cardiovascular, behavioural, motor and endocrine response and in the kidney, where it seems to influence renal hemodynamics but also salt and water excretion, in rat pancreas where it inhibits insulin secretion, in the heart where it seems to play a role in cardiac hypertrophy and fibrosis. In humans high plasma or urine levels of U-II have been described in some pathologic conditions. Peptidic and non peptidic UT receptor antagonists have been synthesized and their effects have been evaluated particularly in animal models of diabetes and heart failure. After promising results in animal models, palosuran, a non peptidic U-II antagonist has been administered also in diabetic patients to evaluate its potential nephroprotective activity. This review presents the data available on the U-II system and its role in physiological and pathological conditions, together with data regarding palosuran and other non peptidic and peptidic U-II antagonists.
Export Options
About this article
Cite this article as:
Cosenzi Alessandro, Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (2) . https://dx.doi.org/10.2174/187152508783955024
DOI https://dx.doi.org/10.2174/187152508783955024 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Inhibition of Sumoylation Alleviates Oxidative Stress-induced Retinal Pigment Epithelial Cell Senescence and Represses Proinflammatory Gene Expression
Current Molecular Medicine Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science Promising Pharmacological, Molecular and Cellular Treatments of Autoimmune Hepatitis
Current Pharmaceutical Design Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions
Current Drug Metabolism Editorial [Hot Topic:Neurodegenerative Disorders: From Molecules to Man (Part 1) (Guest Editors: Giuseppe Di Giovanni, Vincenzo Di Matteo and Ennio Esposito)]
CNS & Neurological Disorders - Drug Targets Immune Mechanism, Aging, Season and Diseases: Modulatory Role of Melatonin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Algorithms for the Diagnosis of wide QRS Complex Tachycardias
Current Cardiology Reviews Ex Vivo and In Vivo Approaches to Study Mechanisms of Cardioprotection Targeting Ischemia/Reperfusion (I/R) Injury: Useful Techniques for Cardiovascular Drug Discovery
Current Drug Discovery Technologies Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis
Current Drug Targets The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Clinical Aspects and Therapeutic Perspectives of Relaxin
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Innovative Strategies in In Vivo Apoptosis Imaging
Current Medicinal Chemistry 3D QSAR Studies on Substituted Benzimidazole Derivatives as Angiotensin II-AT<sub>1</sub> Receptor Antagonist
Current Computer-Aided Drug Design